S993
Clinical - Oligometastatic cancer
ESTRO 2026
References: Tang C, Sherry AD, Haymaker C, et al. Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial. JAMA Oncol. 2023;9(6):825-834. doi:10.1001/jamaoncol.2023.0161Huynh LM, Bonebrake BT, Enke C, Baine MJ. Survival Outcomes After Radiotherapy for the Treatment of Synchronous Oligometastatic Prostate Cancer. JAMA Netw Open. 2022;5(10):e2235345. doi:10.1001/jamanetworkopen.2022.35345 Keywords: M1a prostate cancer, consolidative radiotherapy Long-term follow-up of oligometastatic bone SABR in the BONY-M phase 2, single-arm, multicentre study (NCT05101824) Sebastian M Krog 1 , Mette VO Felter 1 , Nicklas J Spindler 1 , Tine Schytte 2,3 , Tine B Nielsen 2 , Morten H Suppli 4,5 , Laurids Ø Poulsen 6 , Jimmi Søndergaard 6 , Fatma Rahma-Petersen 1 , Hella MB Sand 6 , Tatiana M Abramova 7 , Marie Johansen 7 , Josefine S Kornerup 8 , Mirjam D Alsaker 8 , Henriette Lindberg 1 , Ivan R Vogelius 4 , Claus P Behrens 1,9 , Gitte F Persson 1,10 1 Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark. 2 Department of Oncology, Odense University Hospital, Odense, Denmark. 3 Department of Clinical Research, University of Southern Denmark, Odense, Denmark. 4 Department of Oncology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark. 5 Department of Oncology, Zealand University Hospital, Næstved, Denmark. 6 Department of Oncology, Aalborg University Hospital, Aalborg, Denmark. 7 Department of Radiotherapy, Clinic of Oncology, Ålesund Hospital, Ålesund, Norway. 8 Department of Radiotherapy, Clinic of Oncology, St. Olav University Hospital, Trondheim, Norway. 9 Department of Health Technology, Technical University of Denmark, Kongens Lyngby, Denmark. 10 Department of Clinical Medicine, Faculty of Health, University of Copenhagen, Copenhagen, Denmark Digital Poster Highlight 4946 Purpose/Objective: The multicentre single-arm BONY-M trial included patients with oligometastatic disease (defined as ≤ 5 lesions or ≤ 3 progressing induced lesions) for stereotactic ablative body radiotherapy (SABR) of 37.5 or 30 Gy in three fractions for bone metastases. Patients were enrolled between December 2019 and January 2022 from six centres in Denmark and Norway. One-year local control (primary endpoint), treatment-related side effects, pain response and quality-of-life have previously been presented.[1] This
Conclusion: Consolidative radiotherapy with WPRT and ENI achieved durable disease control and low rates of high-grade toxicity in patients with synchronous M1a HSPC. Predominant out-of-field nodal recurrences highlight the need to optimize elective coverage for retroperitoneal disease. Prospective studies are needed to define the ideal radiotherapy extent.
Made with FlippingBook - Share PDF online